Diabetes Metab J.  2014 Jun;38(3):230-239. 10.4093/dmj.2014.38.3.230.

Current Status of Prescription in Type 2 Diabetic Patients from General Hospitals in Busan

• Suk JH
• Lee CW
• Son SP
• Kim MC
• Ahn JH
• Lee KJ
• Park JY
• Shin SH
• Kwon MJ
• Kim SS
• Kim BH
• Lee SH
• Park JH
• Kim IJ
• Relationship between Cardiovascular Disease and Brachial-Ankle Pulse Wave Velocity (baPWV) in Patients with Type 2 Diabetes (REBOUND) Study Group

• KMID: 2280694
• DOI: http://doi.org/10.4093/dmj.2014.38.3.230

Abstract

BACKGROUND
Data regarding the prescription status of individuals with diabetes are limited. This study was an analysis of participants from the relationship between cardiovascular disease and brachial-ankle pulse wave velocity in patients with type 2 diabetes (REBOUND) Study, which was a prospective multicenter cohort study recruited from eight general hospitals in Busan, Korea. We performed this study to investigate the current status of prescription in Korean type 2 diabetic patients.
METHODS
Type 2 diabetic patients aged 30 years or more were recruited and data were collected for demographics, medical history, medications, blood pressure, and laboratory tests.
RESULTS
Three thousands and fifty-eight type 2 diabetic patients were recruited. Mean age, duration of diabetes, and HbA1c were 59 years, 7.6 years, and 7.2%, respectively. Prevalence of hypertension was 66%. Overall, 7.3% of patients were treated with diet and exercise only, 68.2% with oral hypoglycemic agents (OHAs) only, 5.3% with insulin only, and 19.2% with both insulin and OHA. The percentage of patients using antihypertensive, antidyslipidemic, antiplatelet agents was similar as about 60%. The prevalence of statins and aspirin users was 52% and 32%, respectively.
CONCLUSION
In our study, two thirds of type 2 diabetic patients were treated with OHA only, and one fifth with insulin plus OHA, and 5% with insulin only. More than half of the patients were using each of antihypertensive, antidyslipidemic, or antiplatelet agents. About a half of the patients were treated with statins and one third were treated with aspirin.

Keyword

Diabetes mellitus, type 2; Drug therapy; Hospitals, general

MeSH Terms

Aspirin
Blood Pressure
Busan
Cardiovascular Diseases
Cohort Studies
Demography
Diabetes Mellitus, Type 2
Diet
Drug Therapy
Hospitals, General*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypertension
Hypoglycemic Agents
Insulin
Korea
Platelet Aggregation Inhibitors
Prescriptions*
Prevalence
Prospective Studies
Pulse Wave Analysis
Aspirin
Hypoglycemic Agents
Insulin
Platelet Aggregation Inhibitors

Reference

1. Park Y, Lee H, Koh CS, Min H, Yoo K, Kim Y, Shin Y. Prevalence of diabetes and IGT in Yonchon County, South Korea. Diabetes Care. 1995; 18:545–548.

2. Kim SM, Lee JS, Lee J, Na JK, Han JH, Yoon DK, Baik SH, Choi DS, Choi KM. Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001. Diabetes Care. 2006; 29:226–231.

3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. American Diabetes Association (ADA). European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35:1364–1379.

4. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358:2545–2559.

5. Ko SH, Kim DJ, Oh SJ, Lee HJ, Shim KH, Woo MH, Kim JY, Kim NH, Kim JT, Kim CH, Kim HJ, Jeong IK, Hong EG, Cho JH, Mok JO, Yoon KH, Kim SR. Committee of Clinical Practice Guidelines Korean Diabetes Association. 2011 Clinical practice guidelines for type 2 diabetes in Korea. J Korean Diabetes. 2011; 12:183–189.

6. Chuang LM, Tsai ST, Huang BY, Tai TY. Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia: a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998. Diabet Med. 2002; 19:978–985.

7. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol In adults (Adult Treatment Panel III). JAMA. 2001; 285:2486–2497.

8. R Development Core Team. A language and environment for statistical computing. cited 2007 Dec 5. Available from: http://www.R-project.org.

9. Park SW, Kim DJ, Min KW, Baik SH, Choi KM, Park IB, Park JH, Son HS, Ahn CW, Oh JY, Lee J, Chung CH, Kim J, Kim H. Current status of diabetes management in Korea using National Health Insurance Database. J Korean Diabetes Assoc. 2007; 31:362–367.

10. Lim S, Kim DJ, Jeong IK, Son HS, Chung CH, Koh G, Lee DH, Won KC, Park JH, Park TS, Ahn J, Kim J, Park KG, Ko SH, Ahn YB, Lee I. A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the Committee of the Korean Diabetes Association on the Epidemiology of Diabetes Mellitus. Korean Diabetes J. 2009; 33:48–57.

11. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009; 122:443–453.

12. Morimoto T, Fukui T, Lee TH, Matsui K. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med. 2004; 117:459–468.

13. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, Lee R, Bancroft J, MacEwan S, Shepherd J, Macfarlane P, Morris A, Jung R, Kelly C, Connacher A, Peden N, Jamieson A, Matthews D, Leese G, McKnight J, O'Brien I, Semple C, Petrie J, Gordon D, Pringle S, MacWalter R. Prevention of Progression of Arterial Disease and Diabetes Study Group. Diabetes Registry Group. Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008; 337:a1840.

14. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y. Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008; 300:2134–2141.

15. American Diabetes Association. Standards of medical care in diabetes: 2012. Diabetes Care. 2012; 35:Suppl 1. S11–S63.

16. Park IB, Kim DJ, Kim J, Kim H, Kim H, Min KW, Park SW, Park JH, Baik SH, Son HS, Ahn CW, Oh JY, Lee S, Lee J, Chung CH, Choi I, Choi KM. Current status of aspirin user in Korean diabetic patients using Korean Health Insurance Database. J Korean Diabetes Assoc. 2006; 30:363–371.